SHARE

Catalyst Biosciences Inc (NASDAQ:CBIO) announced recently that they have successfully achieved the positive clinical data from its ongoing Phase 1/2 clinical data in the participants with severe hemophilia B condition. The team was excited by the results that showed the higher potency and advanced pharmacokinetics of CB 2679d.

The findings have numerous advantages over the available approved treatments including the intravenous prophylactic dosages that are renowned to have a prolonged period of low activity levels and reduced risks to the patients according to Nassim Usman, the Catalyst’s president, and CEO. The new results reveal attractive pharmacokinetic and pharmacodynamic of CB 2679d which is based on the potency, the bioavailability, time to maximal concentration, and prolonged life.

The Catalyst’s Factor IX preclinical program which was presented at the International Society on Thrombosis and Haemostasis (ISTH) meeting in July highly supported the launch of the ongoing Phase 1/2 clinical trial of the CB 2679d for subcutaneous prophylaxis. At the meeting, the company presented the Factor VII which supports the introduction of Phase 2/3 clinical tests to assess the subcutaneous dosage amount of marzeptacog alfa (activated), that is expected to start towards the end of the year.

According to Howard Levy the chief medical officer at Catalyst, the new CB 2679d corrected severe hemophilia up to a normal coagulation activity among the patients who were treated with the new subcutaneous doses which included six daily doses. As a result of the new outcome from the study, the company is anticipating to open-label the results from the Phase 1/2 study in participants suffering from hemophilia B according to Levy.

The catalyst which focuses on the development of new treatments to deal with hematology conditions is eager to continue searching for better treatments that would improve the lives of the patients. The company has concentrated on the hemostasis, which covers the subcutaneous prophylaxis of hemophilia and has facilitated the surgery of several individuals with hemophilia especially those with the increased risk of spontaneous bleeding.

LEAVE A REPLY